|Articles|April 1, 2011
Sponsor Oversight of CROs
Author(s)Industry Standards Research
The perennial sponsor complaint: "Outsourcing costs too much." The perennial CRO response: "If you didn't assign so much internal resource to manage us, it would be cheaper."
Advertisement
The perennial sponsor complaint: "Outsourcing costs too much." The perennial CRO response: "If you didn't assign so much internal resource to manage us, it would be cheaper."
Well, it's true and both groups acknowledge it. Over 90% of sponsor and CRO respondents indicate that resources are assigned to oversee outsourced studies. While CROs and sponsors agree that oversight may be excessive, they do not agree on the consequences. In ISR's Staff Quality and Models report, 78% of CROs believe that oversight increases the amount of time necessary to complete a clinical trial compared to only 25% of sponsors. Sponsors hold what may be considered contradictory beliefs regarding their oversight of CROs. They believe their own oversight to be excessive; however many believe there are benefits too. Nearly half of the sponsor respondents indicated oversight reduces time; 53% believe it either reduces costs or has no impact on costs; and 77% believe it increases data quality.
From ISR's perspective, the size, global scope, and complexity of today's clinical trials are justification enough for a degree of oversight. Pharma's business challenge is identifying when enough is enough; the point when investing in more oversight no longer returns a better clinical trial. Service providers' business challenge is to better understand why sponsors insist on oversight, and then develop systems, training, and people to arrive at the right balance.
This is an evolving issue and having a better understanding of development outsourcing models as well as sponsor and service provider oversight rationale are important first steps to increasing trial efficiency and lowering industry clinical development spending. Achieving the right oversight balance can have profound effects on both individual development programs and companies.
—Industry Standard Research, www.ISRreports.com
Articles in this issue
over 14 years ago
Applied Clinical Trials Digital Edition - April 2011over 14 years ago
Business and News Update April 2011over 14 years ago
Demystifying Asian Trialsover 14 years ago
Academic Strength in Germanyover 14 years ago
Imaging CROs in Asiaover 14 years ago
Sponsor Oversight of CROsover 14 years ago
Clinical Research Ethics, Oversight Draws Scrutinyover 14 years ago
Mining for Words: The Case for NLPover 14 years ago
MENA: The Dawn of a New Eraover 14 years ago
Diagnosis on the Run: There's an App for Thatover 14 years ago
Darwin at Work: Trial Technologyover 14 years ago
Alzheimer's Advances Depend on Early Diagnosisover 14 years ago
Act coverover 14 years ago
Research in the United Kingdomover 14 years ago
Researchers Tackle Problems in Bowel DiseaseNewsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- How AI Can Help Physicians Identify Eligible Trials Faster
September 5th 2025
Advertisement
Advertisement